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Abstract: Background: Subclinical mastitis (SCM) is an inflammatory condition of the mammary
gland. We examined the effects of SCM on human milk (HM) composition, infant growth, and HM
intake in a mother–infant cohort from seven European countries. Methods: HM samples were
obtained from 305 mothers at 2, 17, 30, 60, 90, and 120 days postpartum. SCM status was assessed
using HM Sodium (Na): Potassium (K) ratio >0.6. Levels of different macro- and micronutrients were
analyzed in HM. Results: SCM prevalence in the first month of lactation was 35.4%. Mean gestational
age at delivery was lower and birth by C-section higher in SCM mothers (p≤ 0.001). HM concentrations
of lactose, DHA, linolenic acid, calcium, and phosphorous (p < 0.05 for all) was lower, while total
protein, alpha-lactalbumin, lactoferrin, albumin, arachidonic acid to DHA ratio, n-6 to n-3 ratio and
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minerals (iron, selenium, manganese, zinc, and copper) were higher (p < 0.001 for all) in mothers with
SCM. There were no differences in infant growth and HM intake between non-SCM and SCM groups.
Conclusion: We document, for the first time, in a large European standardized and longitudinal
study, a high prevalence of SCM in early lactation and demonstrate that SCM is associated with
significant changes in the macro- and micronutrient composition of HM. Future studies exploring the
relation of SCM with breastfeeding behaviors and developmental outcomes are warranted.
Keywords: subclinical mastitis; European population; human milk; longitudinal study; milk macronutrients
1. Introduction
Subclinical mastitis (SCM) is an asymptomatic, inflammatory condition of the lactating mammary
gland [1] associated with early lactation failure [2] and poor infant weight gain [1,3]. Studies among
different ethnicities have reported varying estimates of SCM prevalence reaching to as high as
66% with most of the cases occurring in early lactation and typically declining over time [1,4,5].
Manifestation of SCM is seen as a mammary gland inflammation often due to milk stasis [6],
infection [7], and/or micronutrient deficiency [8]. Occasionally, SCM may progress to clinical mastitis,
presenting with symptoms such as fever, mammary gland pain and reddening, combined with breast
engorgement [9–11]. Clinical and subclinical mastitis share certain unique clinical features that
include unilateral orientation, and elevated milk sodium and interleukin-8 (IL-8) concentration, which
also serve as the diagnostic markers for identifying these conditions [12]. The pathophysiological
changes occurring in the inflammatory mammary gland of SCM mothers comprise involuntary
opening of the tight junctions around alveolar cells due to transient release of cytokines, damaging
the mammary epithelial layer with resultant increase in permeability [1]. The net outcome of this
enhanced permeability is increased sodium and decreased potassium concentration in the Human
Milk (HM) which routinely forms the basis for employing an elevated sodium: Potassium (Na:K) ratio
as a diagnostic tool for SCM in humans [12,13]. This is also supported by the studies reporting more
immune cells, increased sodium, chloride, immunoglobulins [14,15], and decreased concentration
of lactose [14–16], calcium, phosphorus, and potassium in the bovine milk of SCM cows [14,17].
In addition, Na:K ratio is reported to be a better indicator of SCM due to higher precision and accuracy
in comparison to other diagnostic markers [17].
Data on SCM among humans are scarce and inconsistent. The lack of consistency may be attributed
to the fact that most of our knowledge is extrapolated from preclinical studies [18–22], and the limited
number of clinical observations offer several limitations. Most clinical studies are focused on the
elevated cytokines or changes in inflammatory mediators occurring in the HM of SCM mothers in the
absence of data about milk intake and/or infants’ growth [8,17,23]. However, study on milk intake by
infants of SCM mothers failed to take into account the compositional changes occurring in the HM [24].
Lastly, numerous studies on HIV-infected SCM mothers reported elevated HIV viral load in milk of
SCM mothers, increasing risk of HIV transmission to the newborns [3,5,12,13,25].
We conducted a prospective, longitudinal study in a large European cohort to determine the
association of SCM with the composition of HM with a secondary interest to compare the milk intake
and growth of infants born to SCM versus non-SCM mothers. To the best of our knowledge, this is the
first report among European lactating mothers describing altered composition of several macro- and
micronutrients in the HM of mothers with SCM.
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2. Materials and Methods
2.1. Study Design and Population
The data presented in this longitudinal, observational study named ATLAS were collected at
13 centers across seven European countries between December 2012 and January 2016. The study
centers were selected in order to have a geographical spread that could potentially reflect the variability
in the HM composition (centers from Sweden and Norway representing the Nordic countries; centers
from Italy Portugal, and Spain representing Western and Southern Europe; centers from France
representing central Europe; and centers from Romania representing Eastern Europe). Each of the
study sites was evaluated for site feasibility and these were finalized based on availability of resources
at facilities. The study was approved by the institutional and local ethical boards for each center and
was registered at ClincalTrials.gov with identifier NCT01894893. A written informed consent was
provided by all mothers in their respective local languages.
Pregnant women were screened at clinical sites for the fulfillment of the following inclusion
criteria: Aged between 18 to 40 years, especially in last trimester; body mass index (BMI) between
19 and 29, both inclusive; intend to breastfeed for at least four months; and willing to comply with the
study protocol. Women who did not meet any inclusion criteria or presented with condition or on
medication that contraindicate breastfeeding were excluded from the study. The mother–infant pairs
enrolled into this study were observed during regularly scheduled visits carried out at Day 2, 17, 30,
60, 90, and 120 postpartum. This study was designed to investigate the impact of SCM (diagnosed
as Na:K ratio in HM >0.6) on milk composition and the association between SCM, HM-intake and
infant growth.
2.2. Maternal and Infant Characteristics
Maternal and infant data were collected by trained and certified research nurses and assistants.
Maternal characteristics included demography, anthropometry, medical history, and medication use.
Infant characteristics included anthropometry, infant intake diary (three centers in France), and
medication use.
2.3. Collection of HM Samples and Diagnosis of SCM
A standardized procedure was employed to collect milk samples from the same breast throughout
the study period using an electric breast pump (Medela Symphony, Switzerland) at a scheduled time
of 11:00 ± 2:00 h to avoid circadian influence. To achieve full milk extraction of the single breast,
all enrolled mothers were asked to empty the breast in the previous feed. During the scheduled visit,
the selected breast was emptied completely, and an aliquot of 40 mL was reserved for further analysis.
The rest was returned to the mother for feeding the infant. Each sample was collected in a labeled
freezing tube and stored at −18 ◦C until it was delivered to the Nestlé Research Centre (Lausanne,
Switzerland) where it was stored at −80 ◦C for further analysis.
SCM status was assessed using HM sodium potassium ratios (Na:K). Lactating mothers were
categorized in to two groups: those having SCM (defined as Na:K ratio >0.6) versus normal (defined
as Na:K ratio ≤0.6) based on the Na:K ratios in HM in early lactation (days 2, 17, and 30) [17].
Lactating mothers having at least one incidence of SCM during any of these three time points were
classified as SCM, while those in the normal category did not have any incidence of SCM in any of
these time points. The cut-offs are based on the published literature on human SCM [12,13,17].
2.4. Macronutrient Composition of HM
Levels of lactose, lipid, and energy were measured in HM samples employing HM analyzer
generation 3 (MIRIS AB, Uppsala, Sweden) supported by XMA-SW software version 2.87, that works
on the principle of semisolid middle infrared (MIR) transmission spectroscopy. All samples were
homogenized for 3 × 10 s using a sonicator (MIRIS AB, Uppsala, Sweden) and were kept in a water
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bath at 40 ◦C prior to measurement. An in-house control sample was analyzed after every tenth
measurement for quality control purposes.
Fatty acid (FA) profile—18:3 N-3-Octadecatrienoic Acid (linolenic acid), 22:6 N-3-Docosahexanoic
Acid (DHA), arachidonic acid to DHA ratio (ARA/DHA ratio), n-6 to n-3 ratio—was determined by the
procedure of Cruz-Hernandez et al. [26]. The analysis of methyl esters of FA (FAMEs) was performed
by gas chromatography using a CP-Sil 88 capillary column (100 m, 0.25 mm, id. 0.25 µm film thickness)
and their identification was done by comparing the retention time with authentic standards (GC
standard Nestlé 36 from NuCheck-Prep, Elysan, MN, USA).
Total protein content in HM was measured using the colorimetric bicinchoninic acid (BCA)
method according to the manufacturer’s protocol of BCA assay kit (ThermoFisher Scientific, Waltham,
MA, United States). The four major HM proteins: alpha-lactalbumin, lactoferrin, serum albumin,
and caseins were quantified using a LabChip system [27].
2.5. Mineral and Trace Elements Concentration of HM
Quantification of minerals—Sodium (Na), Magnesium (Mg), Phosphorous (P), Potassium (K),
Calcium (Ca), Manganese (Mn), Iron (Fe), Copper (Cu), Zinc (Zn) and Selenium (Se)—were carried out
using an internal methodology based on inductively coupled plasma mass spectrometry (ICP-MS),
PerkinElmer model NexION 300. HM sample (0.7 mL) was transferred into perfluoroalkoxy alkane
vessels and mineralized in a CEM® Microwave digestion system using HNO3/H2O2. Mineralized
samples were transferred to polyethylene tubes, diluted with Milli-Q water. Germanium (Ge) and
Tellurium (Te) were added as internal standards. Quantification was realized by ICP-MS using He or
CH4 as collision or reaction gas. Certified Reference Materials were added to all analytical series to
control the quality of the quantification.
2.6. Estimation of Milk Intake by Test Weighing Technique
A modified test weighing method was employed to determine the HM intake in a subset of the
infants [28]. The procedure involved mothers test weighing their infants using an electronic balance
(Seca 354) before and after the selected feeding sessions for three times on a single day as close as
possible to an upcoming study visit. All enrolled mothers recorded the infant weight and number of
feeds in the diaries provided by the study center and the calculations were made by the study staff to
estimate the milk intake per feed. Daily milk intake was estimated by taking the average of three feeds
and multiplying by the total number of feeds on that day.
2.7. Infant Growth Parameters
All growth parameters were assessed using standard procedure by trained personnel. Infants
were weighed without clothing or diaper in the same electronic scale (Seca 354) throughout the study
period. Length was measured in the recumbent position using a standardized length board taking care
of complete alignment and full body extension with flexed feet. Head circumference was measured by
a standard non-elastic plastic-covered measurement tape to the nearest 1 mm.
2.8. Statistical Analysis
All statistical analyses were done using R version 3.2.3. The descriptive statistics for continuous
variables are presented with number (n) of subjects, mean and standard deviation; for categorical data
number (n) with percentage (%) are presented.
For comparison of HM composition between mothers with SCM versus normal, a linear mixed
model was applied explaining the milk concentration (of a particular nutrient) with the age of infant,
SCM status (including the interaction between the age and the SCM status), the country of origin, the
mode of delivery, and the gestational age of the infant at birth. Global estimates were calculated using
analysis of variance on the model to identify variables significantly influencing the milk concentration.
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For comparison of infant growth parameters between mothers with SCM and normal, a linear
mixed model was applied explaining the infant’s growth (Z-scores: weight for age, weight for length,
length for age, BMI for age and head circumference for age) with visit, SCM status (including the
interaction between visit and the SCM status), the baseline value of the corresponding growth parameter
(value at first visit), and the gestational age of the infant at birth. The WHO growth charts were used
for calculation of Z-scores.
For comparison of infant milk intake between mothers with SCM and normal, a linear mixed
model was applied explaining the milk intake with visit, SCM status (including the interaction between
visit and the SCM status), the breastfeeding compliance of infant, and the weight of infant per visit.
This exercise was performed for daily milk intake, average milk intake per feeding, as well as number
of feeds per day.
Contrast estimates were calculated per visit by comparing mothers with and without SCM.
Statistical significance is considered when p-values are <0.05.
3. Results
3.1. Study Population
A total of 331 out of 370 screened pregnant women from seven European countries reached to
baseline for further analysis. Detailed description about number of women at all six visits is outlined
in Figure 1.
Figure 1. Flowchart outlining number of mothers per group at each visit. The Subclinical mastitis
(SCM) group in this flowchart indicates mothers with at least one incident of SCM in the first month.
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3.2. SCM Prevalence
Figure 2 shows the percentage of mothers with SCM across the first four months of lactation,
with the highest prevalence reported at day 2 (39.6%) and thereafter decreasing over the four-month
period (9.8% at day 17, 5% at day 30, 2.5% at day 60, 4.4% at day 90, and 5% at day 120). As our definition
of SCM stated previously (at least one incidence of SCM during day 2, 17, and 30), the proportion
of mothers having SCM was 35.4% (108 out of 305 mothers). There were no significant differences
between the proportions of dropouts in SCM vs. normal mothers.
Figure 2. Frequency of SCM in a European cohort of lactating mothers across four months of lactation.
3.3. Maternal and Infant Characteristics
Maternal and infant characteristics of both (SCM and normal) groups adjusted for visit, country,
delivery mode, and gestational age are shown in Table 1. A total of 108 lactating mothers participating
from different European countries were diagnosed with SCM. The anthropometric indicators like
maternal age, height, pre-pregnancy weight, BMI, and parity were not significantly different between
the SCM and normal groups. However, there were significant country-wise differences in the frequency
of SCM (p < 0.001). Notably the gestational age at delivery was significantly lower among mothers
with SCM compared to normal (p < 0.001). Similarly, the rates of caesarean mode of delivery were
higher among mothers with SCM (p < 0.001) and the infant birth weights were also significantly low
(p = 0.001) compared to their normal counterparts.
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Table 1. Maternal and infant characteristics by presence or absence of SCM.
SCM
(N = 108), n (%)
Normal
(N = 197), n (%) p Value
Maternal Characteristics
Age (y) a 31.44 ± 4.42 31.17 ± 4.09 0.596
Country of residence b
Spain (56% SCM prevalence) 5 (4.8) 4 (2.0)
<0.001
France (24% SCM prevalence) 21 (20.2) 67 (34.0)
Italy (7% SCM prevalence) 1 (1.0) 14 (7.1)
Norway (0% SCM prevalence) 0 (0.0) 10 (5.1)
Portugal (37% SCM prevalence) 36 (33.3) 62 (31.5)
Romania (67% SCM prevalence) 28 (25.9) 14 (7.1)
Sweden (40% SCM prevalence) 17 (15.7) 26 (13.2)
Height (cm) a 164.86 ± 6.06 164.89 ± 5.99 0.964
Pre-pregnancy weight (kg) a 61.79 ± 8.18 61.63 ± 7.49 0.866
Pre-pregnancy BMI (kg/m2) a 22.73 ± 2.78 22.67 ± 2.52 0.847
BMI category b
Normal weight 85 (78.7) 158 (80.2)
0.871Overweight 23 (21.3) 39 (19.8)
Parity b
0.503Primiparous 84 (77.8) 141 (71.6)
Multiparous 24 (22.2) 56 (28.4)
Table 1. Cont.
SCM
(N = 108), n (%)
Normal
(N = 197), n (%) p Value
Gestational age at delivery (wk) a 39.07 ± 1.23 39.56 ± 1.13 0.001
Mode of delivery b
Caesarian 41 (38.0) 35 (17.8)
<0.001Vaginal 67 (62.0) 162 (82.2)
Infant Characteristics
Infant weight at birth (kg) a 3.23 (0.51) 3.42 (0.44) 0.001
Infant length at birth (cm) a 49.69 (2.21) 50.13 (1.97) 0.086
Infant gender b
Female 46 (42.6) 93 (47.2)
0.513Male 62 (57.4) 104 (52.8)
a Continuous variables are presented by mean ± SD and analyzed using t-test. b Categorical variables are presented
by n (%) and analyzed chi-square/Fisher’s exact test.
3.4. Macronutrient Composition of HM
Essential macronutrients were examined in the milk of SCM and normal mothers as shown in
Table 2. While there were no differences in the levels of energy and fat in the milk from mothers of both
groups, the levels of lactose were significantly lower in the milk from SCM mothers (based on overall
comparison across the six visits) (p < 0.001), with specific time point differences observed at day 2, 17,
and 30 (p < 0.05 for all). The HM concentration of total protein was also significantly higher in SCM
mothers compared to normal mothers (based on overall comparison across the six visits) (p < 0.0001),
with specific time point difference only at day 2 (p < 0.001).
Nutrients 2020, 12, 105 8 of 18
Table 2. Composition of Human Milk (HM) across four months of lactation by presence or absence
of SCM.
Mean ± SD Day 2 Day 17 Day 30 Day 60 Day 90 Day 120 Overall pValue 1
Energy
(kcal/100
mL)
SCM
60 ± 10 69 ± 10 71 ± 14 72 ± 13 70 ± 15 70 ± 14
0.13
(n = 36) (n = 91) (n = 80) (n = 77) (n = 70) (n = 68)
Normal
62 ± 9 73 ± 12 72 ± 13 72 ± 15 71 ± 16 72 ± 17
(n = 55) (n = 172) (n = 156) (n = 153) (n = 150) (n = 136)
Lactose
(g/100 mL)
SCM
6.7 ± 0.5 * 7.2 ± 0.4 * 7.3 ± 0.4 * 7.2 ± 0.4 7.3 ± 0.3 7.3 ± 0.3
<0.001
(n = 36) (n = 91) (n = 80) (n = 78) (n = 71) (n = 68)
Normal
7.0 ± 0.3 7.3 ± 0.3 7.4 ± 0.3 7.3 ± 0.3 7.3 ± 0.3 7.3 ± 0.3
(n = 55) (n = 172) (n = 157) (n = 153) (n = 150) (n = 139)
Total
protein
(g/100 mL)
SCM
2.7 ± 1.1 ** 1.7 ± 0.4 1.5 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3
<0.0001
(n = 104) (n = 104) (n = 91) (n = 80) (n = 77) (n = 77)
Normal
2.5 ± 1.1 1.6 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.5
(n = 150) (n = 188) (n = 171) (n = 162) (n = 155) (n = 147)
Total fat
(g/100 mL)
SCM
2.6 ± 1.0 3.7 ± 1.1 4.0 ± 1.5 4.2 ± 1.5 4.0 ± 1.7 4.0 ± 1.5
0.11
(n = 41) (n = 92) (n = 80) (n = 78) (n = 71) (n = 68)
Normal
2.9 ± 1.0 4.2 ± 1.4 4.1 ± 1.4 4.1 ± 1.6 4.0 ± 1.8 4.2 ± 1.8
(n = 55) (n = 173) (n = 156) (n = 153) (n = 150) (n = 136)
1 The macronutrient composition of HM across lactation was analyzed by using linear mixed model with milk
concentration (of a particular nutrient) as dependent variable with the age of infant, SCM status, interaction between
the age and the SCM status, the country of origin, the mode of delivery, and the gestational age of the infant at birth
as explanatory variables. * Statistical significance of the difference between mothers with SCM and without SCM for
a particular time point with p value <0.05, ** with p value <0.001.
Quantification of four major HM proteins revealed that the levels of alpha-lactalbumin, lactoferrin,
and albumin in milk of SCM mothers were higher when compared to normal (based on overall comparison
across the six visits) (p < 0.001 for all) (Figure 3). More specifically, for alpha-lactalbumin significant
differences were observed at day 2 and 60; for lactoferrin at day 2, 17, 30, 60 and 90; and for albumin at
day 2, 17, 30, 60 (p < 0.05 for all). Total caseins were not significantly different between the two groups.
Figure 3. Concentrations of individual proteins in HM across lactation by presence or absence of SCM.
* Statistical significance of the difference between mothers with SCM and without SCM for a particular
time point with p value <0.05, ** p value for overall difference between groups <0.001.
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The fatty acid profile of HM from SCM mothers contained lower 22:6 (n-3) docosahexanoic acid
(DHA) and 18:3 (n-3) octadecatrienoic acid (linolenic acid), while levels of arachidonic acid to DHA
ratio, and n-6 to n-3 ratio were higher than the normal group (based on overall comparison across the
six visits) (p < 0.001 for all) (Figure 4). More specifically, per time point differences were seen only for
18:3 (n-3) octadecatrienoic acid at day 17 (p < 0.05).
Figure 4. Concentrations of fatty acids in HM across lactation by presence or absence of SCM. * Statistical
significance of the difference between mothers with SCM and without SCM for a particular time point
with p value <0.05, ** p value for overall difference between groups <0.001.
3.5. Mineral and Trace Element Concentration in HM
Milk of SCM mothers had significantly lower calcium (p = 0.003) and phosphorus (p < 0.0001),
while iron, selenium, manganese, zinc (p < 0.0001 for all), and copper (p < 0.001) were significantly
higher in the HM of SCM mothers compared to their adjusted normal group (based on overall
comparison across the six visits, Table 3). Considering per time point, significant differences were
observed for calcium, selenium, copper, manganese, and zinc at day 2 (p < 0.05), iron at day 2 and 17
(p < 0.05 for both), and for phosphorus at day 2, 17, and 30 (p < 0.05 for all).
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Table 3. Mineral and trace element concentrations of HM across four months of lactation by presence
or absence of SCM.
Day 2 Day 17 Day 30 Day 60 Day 90 Day 120 Overall pValue 1
Calcium
(mg/L)
SCM
256 ± 73 * 281 ± 54 296 ± 47 299 ± 41 288 ± 45 271 ± 36
0.003
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
295 ± 72 293 ± 55 296 ± 51 301 ± 45 297 ± 48 284 ± 42
(n = 111) (n = 192) (n = 174) (n = 166) (n = 156) (n = 148)
Phosphorus
(mg/L)
SCM
109 ± 41 * 150 ± 31 * 149 ± 29 * 138 ± 21 128 ± 18 126 ± 20
<0.0001
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
144 ± 32 169 ± 28 155 ± 24 139 ± 21 133 ± 20 131 ± 22
(n = 111) (n = 192) (n = 174) (n = 166) (n = 156) (n = 148)
Iron (µg/L)
SCM
601 ± 392 * 461 ± 310* 346 ± 162 292 ± 141 264 ± 140 216 ± 103
<0.0001
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
415 ± 193 389 ± 186 326 ± 137 278 ± 132 245 ± 127 262 ± 502
(n = 111) (n = 192) (n = 174) (n = 166) (n = 156) (n = 148)
Selenium
(µg/L)
SCM
37 ± 19 * 19 ± 6 15 ± 3 12 ± 3 10 ± 2 9 ± 2
<0.0001
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
26 ± 12 18 ± 3 15 ± 3 12 ± 2 10 ± 2 10 ± 6
(n = 111) (n = 192) (n = 174) (n = 166) (n = 156) (n = 148)
Manganese
(µg/L)
SCM
6.6 ± 3.9 * 4.4 ± 1.6 3.7 ± 1.1 4.5 ± 3.4 3.4 ± 0.8 3.7 ± 0.9
<0.0001
(n = 79) (n = 41) (n = 26) (n = 22) (n = 19) (n = 13)
Normal
5.8 ± 3.1 3.9 ± 1.3 3.5 ± 1.0 3.4 ± 0.9 3.3 ± 0.7 4.0 ± 2.2
(n = 92) (n = 103) (n = 75) (n = 45) (n = 36) (n = 37)
Zinc (µg/L)
SCM
7975 ± 3093 * 3234 ± 1274 2422 ± 906 1616 ± 1208 1113 ± 521 996 ± 520
<0.0001
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
7178 ± 2734 3590 ± 1051 2686 ± 872 1599 ± 692 1219 ± 571 1031 ± 563
(n = 111) (n = 192) (n = 174) (n = 166) (n = 153) (n = 148)
Copper
(µg/L)
SCM
533 ± 267 * 529 ± 135 423 ± 86 325 ± 74 268 ± 72 221 ± 69
<0.001
(n = 91) (n = 97) (n = 84) (n = 78) (n = 74) (n = 71)
Normal
472 ± 175 522 ± 111 422 ± 89 304 ± 76 256 ± 77 228 ± 89
(n = 111) (n = 192) (n = 174) (n = 166) (n = 156) (n = 148)
1 The mineral and trace element concentrations of HM across lactation were analyzed by using linear mixed model
with milk concentration (of a particular mineral and trace element) as dependent variables with the age of infant,
SCM status, interaction between the age and the SCM status, the country of origin, the mode of delivery, and the
gestational age of the infant at birth as factors. * Statistical significance of the difference between mothers with SCM
and without SCM for a particular time point with p value <0.05.
3.6. SCM Status and HM Intake
Feeds per day (feeding frequency) and HM intake by test weighing were recorded and daily
intake estimated for a subset of infants from three French sites between the two groups, as described in
Table 4.
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Table 4. Pattern of infants born to SCM and normal mothers at each time point.
Days Postpartum
Feeding Frequency (per day) Intake Per Feed (kg/feed) Daily intake (kg/day)
Median Average Median Average Median Average
(Q1, Q3) (± SD) (Q1, Q3) (± SD) (Q1, Q3) (± SD)
Day 2 SCM 9 (8, 10.75) 9.56 ± 2.25 0.02 (0.01, 0.04) 0.03 ± 0.03 0.21 (0.12, 0.36) 0.29 ± 0.22
Normal 9 (8, 11) 9.54 ± 2.55 0.03 (0.02, 0.04) 0.03 ± 0.02 0.27 (0.18, 0.35) 0.28 ± 0.15
Day 17 SCM 8 (6.75, 8) 7.80 ± 1.51 0.07 (0.04, 0.10) 0.07 ± 0.04 0.52 (0.36, 0.74) 0.55 ± 0.24
Normal 9 (7, 10) 8.9 ± 1.95 0.07 (0.05, 0.09) 0.07 ± 0.04 0.60 (0.45, 0.70) 0.61 ± 0.20
Day 30 SCM 7.5 (7, 9) 7.94 ± 1.95 0.09 (0.06, 0.11) 0.09 ± 0.04 0.66 (0.57, 0.73) 0.67 ± 0.18
Normal 8 (7, 10) 8.39 ± 1.88 0.09 (0.06, 0.12) 0.09 ± 0.04 0.70 (0.54, 0.87) 0.73 ± 0.25
Day 60 SCM 7 (6,8) 7.24 ± 1.64 0.10 (0.06, 0.13) 0.10 ± 0.04 0.72 (0.61, 0.82) 0.69 ± 0.18
Normal 7 (6, 8) 7.13 ± 1.78 0.11 (0.08, 0.14) 0.11 ± 0.05 0.75 (0.60, 0.90) 0.77 ± 0.27
Day 90 SCM 7 (6, 8.25) 7.33 ± 1.78 0.12 (0.10, 0.14) 0.12 ± 0.03 0.94 * (0.68, 1.03) 0.89 * ± 0.25
Normal 6 (5, 7) 6.26 ± 1.58 0.12 (0.09, 0.16) 0.13 ± 0.05 0.75 (0.62, 0.90) 0.76 ± 0.21
Day 120 SCM 6 (6, 7.5) 6.47 ± 1.36 0.13 (0.08, 0.15) 0.12 ± 0.05 0.75 (0.66, 0.81) 0.72 ± 0.25
Normal 6 (5, 7) 5.94 ± 1.62 0.13 (0.09, 0.17) 0.14 ± 0.06 0.73 (0.66, 0.91) 0.77 ± 0.23
* p = 0.032.
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The median (Q1, Q3) per feed intake (kg) of milk by infants at each time point (day 2, 17, 30,
60, 90, and 120) was 0.026 (0.016, 0.04), 0.07 (0.04, 0.09), 0.09 (0.06, 0.11), 0.1 (0.07, 0.14), 0.12 (0.09,
0.16), 0.13 (0.09, 0.16), respectively. Similarly, the median daily intake (kg) of HM by infants at each
time point (day 2 till day 120) was 0.27 (0.17, 0.36), 0.6 (0.43, 0.72), 0.68 (0.54, 0.84), 0.72 (0.60, 0.88),
0.76 (0.62, 0.96), 0.75 (0.66, 0.88), respectively (data not shown). There was no difference in feeding
frequencies and per feed intake by infants of SCM and normal mothers. The statistical modeling
without covariates also showed no differences between groups at any time points except at day 90,
where a slightly higher median was observed for SCM group. We further incorporated infant weight
and breastfeeding behavior (exclusively, partially, or predominantly) as covariates in the model and
observed that among a partially breastfed group of SCM mothers, infants consumed significantly (p =
0.032) higher daily intake of milk compared to their non-SCM counterparts at day 90. However, this
was not observed in the exclusively and predominantly breastfed group suggesting a possibility of
compensatory behavior by infants for overall milk intake amongst the partially breastfed subset.
3.7. Infant Growth Parameters
Infants born to mothers with SCM had smaller head circumference (p < 0.0001), weight (p = 0.0005),
weight for length (p = 0.004), and BMI (p = 0.0005) at birth, in addition to having a lower gestational
age at birth, as shown in Table 5. However, the differences disappeared as lactation progressed and
anthropometric measurements were not statistically significant between groups across the study.
Table 5. Growth parameters of infants of SCM and normal mothers.
V0 (Child Birth) Overall Effect
Z Score Estimate SCM vs.Normal (SE) p Value
Estimate SCM vs.
Normal (SE) 1 p Value
1
BMI −0.477 (0.134) 0.0005 0.032 (0.066) 0.624
Head circumference −0.581 (0.135) <0.0001 −0.022 (0.056) 0.696
Length −0.251 (0.130) 0.059 −0.073 (0.053) 0.165
Weight −0.430 (0.121) 0.0005 0.011 (0.049) 0.831
Weight for length −0.421 (0.142) 0.004 0.056 (0.073) 0.448
1 The infant’s growth Z-scores were analyzed by using linear mixed model with Z-score of different growth parameter
as dependent variable with the age of infant, SCM status, interaction between age and the SCM status, the baseline
value of the corresponding growth parameter and the gestational age of the infant at birth as explanatory variable.
4. Discussion
This study reported 35.4% SCM prevalence during the first month of lactation among European
mothers using a diagnostic marker of HM Na:K ratio >0.6. The great majority of cases were in the
first two days of lactation, ranging from 40% at day 2 to 10% at day 17. The prevalence of SCM in our
cohort decreased with the progression of lactation (two months and later). These observations are in
agreement with a recent study on Guatemalan mothers that reported SCM prevalence of 30% between
5 and 17 days of lactation which reduced to 15.6% between 18 and 46 days of lactation [17]. There are
wide variations in the estimate of SCM prevalence from data among different ethnicities [1,4,5,8].
This variation may be attributed to the lactation stage taken into consideration or differences in SCM
definitions that include milk Na:K >1.0 [4] or milk Na:K >0.6 to ≤1 [4] or milk leukocyte count >1
million cells/mL [5].
4.1. Maternal and Infant Characteristics
In our dataset we observe that normal mothers and those with SCM are different in terms of
country representation. Notable differences are Romania (26% of SCM group while only 7% of the
normal group) and France (20% for SCM group while 34% in normal group). Romania had the highest
incidence rate of SCM at 67% (total number of mothers = 42) while the lowest incidence rate can be
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found in Norway with 0 incidents of SCM (total number of mothers = 10). This significantly different
distribution of SCM in the European countries may be indirectly associated with the differences in the
breastfeeding practices and/or the mode of delivery being practiced in these countries as reported by
an Euro-Peristat study that also mentions a higher proportion of C-sections being followed in countries
such as Portugal and Romania [29]. Previous literature also shows that women undergoing C-sections
have a greater likelihood of developing mastitis [30]. We recorded a similar observation of higher SCM
incidence in mothers who underwent caesarean mode of delivery (p < 0.001). This C-section associated
SCM may be attributed to the delay in breastfeeding consequently leading to breast engorgement,
milk stasis, and inadequate breast emptying [9]. There was no significant difference in the maternal
age, height, pre-pregnancy weight, BMI, parity, infant’s length, and gender between the SCM and
normal groups. However, mothers with SCM had significantly shorter gestational age at delivery and
their infants were of lower weight at birth when compared to normal mothers.
4.2. Macronutrient Composition of HM
To the best of our knowledge, this is the first report to demonstrate the altered levels of
macronutrients in the HM of mothers with SCM versus those without in a cohort of European
population, although there are a few similar observations from mothers with mastitis of different
ethnicities [31,32].
In HM, lactose is the main sugar that works as an osmotic regulator [31]. We observed significantly
lower lactose concentrations in the HM of SCM mothers. This observation is corroborated by the
studies of Prentice et al. and Fetherston et al. that reported a similar finding [33,34]. Diminished lactose
levels in the milk of mothers with breast infection is also reported by the study of Ramadan and
coworkers [35]. This decreased lactose in the milk of mothers with mastitis may be attributed to its
leaking into the bloodstream, whereas in the infected HM reduced biosynthesis is postulated as the
possible mechanism for low lactose [33–35]. Depending on the magnitude of SCM condition, one or
both might be the possible mechanism(s) to reduce lactose in milk of SCM mothers. In our cohort, we
did not observe any differences in the energy values of HM between mothers with SCM and those
without. To the contrary, Say and coworkers observed lower HM energy levels in mastitic mothers from
Turkey in a case-control study. The authors postulated this effect as a result of decreased milk synthesis,
enhanced permeability of blood–milk barrier and/or increased proteolytic/enzymatic activity [31].
Our study reported higher levels of total protein and specific proteins in the milk of mothers with
SCM. Most of the information available today either comes from bovine studies or from comparing
lactating mothers with and without mastitis, and results are conflicting. In dairy bovine herds
experiencing intramammary infection, the non-casein nitrogen fraction was found to be elevated, while
the casein content and casein-to-total protein were lower compared to normal quarters. The authors
postulated this to be due to increased proteolysis resulting from the elevation of plasmin or other
proteases derived from somatic cells, leading to the breakdown of casein and the influx of blood proteins
that are relatively resistant to proteolysis (e.g., immunoglobulins, IgG, and bovine serum albumin) into
milk via the paracellular pathways that proliferate during mastitis [36]. Similar observations were also
made in seasonally calving dairy herds where milk from cows with mastitis had higher concentrations
of total protein, non-casein proteins, but lower concentrations of casein proteins compared to milk
from healthy cows [37]. No significant differences were observed in the HM protein levels between
Turkish mothers with and without mastitis, and the authors attributed this to ethnic differences,
differences in maternal nutritional status and dietary intake, breastfeeding patterns and differences in
milk measurement techniques [31]. The evidence with respect to specific proteins such as lactoferrin is
also conflicting where in some studies it is shown to be increased in mothers with mastitis [34] while
in others it does not demonstrate an increase, despite an increase in other milk components such as
IL-1ß and IL-6 [38]. The observed higher levels of proteins in mothers with SCM may be related to the
opening of the tight junctions and the influx of plasma proteins into milk that may have exceeded
the enzymatic breakdown of proteins synthesized de novo resulting in a net increase in total protein.
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Typically, proteins such as alpha lactalbumin have components such as bioactive peptides that possess
antibacterial properties [39].
Fat is the most variable macronutrient present in breast milk [31]. Also, reported data offer
intriguing evidences of lipolysis due to inflammation [31]. Consequently, a number of studies have
reported low fat concentration in the milk of mastitic mothers attributed to the given mechanism
or reduced synthetic or secretory capacity of the mammary gland [31,37]. However, in our data set,
we did not observe any differences in the HM fat between the two groups.
Ours is the first study to report that SCM is associated with alteration of the levels and ratios
of HM fatty acids. The milk of mothers with SCM had lower levels of 22:6 n-3-docosahexanoic acid
(DHA) and 18:3 n-3 –octadecatrienoic acid (linolenic acid), while higher arachidonic acid to DHA ratio,
and n-6 to n-3 ratio compared to normal mothers. This observation points towards a pro-inflammatory
state of SCM, whereby the low milk DHA levels in SCM mothers might be associated to its uptake
for attenuating inflammation, since it is a known precursor of resolvins (compounds that resolve
inflammation) [40].
4.3. Mineral and Trace Element Concentration in HM
Our data shows higher levels of iron, selenium, manganese, zinc, and copper in the milk of
mothers with SCM and lower levels of calcium and phosphorus. The role of selenium in preventing
mastitis has been well documented in bovine studies. Deficiency of selenium is associated with reduced
and impaired polymorphonuclear neutrophils activity (PMN), thereby influencing cell phagocytic
capacity, bactericidal activity or both [41]. Dietary supplementation of cows with selenium and vitamin
E results in a more rapid PMN influx into milk following intramammary bacterial challenge and
increased intracellular killing of ingested bacteria by PMN, as well as lowering the frequency and
shortening the duration of clinical mastitis [42,43]. Selenium is known to exhibit anti-inflammatory
effects and can attenuate inflammation possibly by inhibiting the activation of NF-κB by modulating
selenoprotein genes expression [44] The only other study in humans that has investigated the impact
of SCM on milk mineral concentrations was a cross-sectional study among lactating mothers from
Guatemala. HM samples were obtained during transitional lactation (5–17 days), early lactation
(18–46 days) and established lactation (4–6 months) and mineral concentrations were analyzed using
the similar methodology as ours. Interestingly, they also found that SCM was associated with higher
levels of selenium and lower levels of phosphorus in the HM, even after controlling for the lactation
stage. The authors concluded that the accumulation of selenium in the HM of SCM mothers may be an
indirect consequence of hyper-accumulation of selenium at the inflamed site and may be an important
defense mechanism for the mammary gland against SCM pathogens [17]. Similar to selenium, we also
observed for the first time higher concentrations of iron, manganese, zinc, and copper in the milk of
mothers with SCM and this may be again a mechanism to combat inflammation. Previously animal
studies have shown that supplementation with copper and zinc reduces the somatic cell count in
milk and enhances the immune system [45,46]. Deficiencies in minerals such as selenium, copper,
and zinc can lead to prolonged inflammation, increased accumulation of reactive oxygen species,
reduced immune cell proliferation and activity, as well as diminished ability for intracellular killing of
mastitis pathogens. Reports from studies in cows with mastitis also indicate a decrease in milk calcium
concentrations of up to 11% [47]. Additionally, lower serum levels of calcium have been associated with
impaired phagocytosis and with lower neutrophil activation in cows [48] The lower concentrations of
phosphorus observed in the HM of mothers with SCM might be related to its increased incorporation
into Adenosine triphosphate for energy production due to inflammation.
4.4. SCM Status and HM Intake
Evaluation of HM intake is often done in clinical as well as research settings for various purposes.
The double label water technique is usually referred to as a reference method but is resource intensive
and bears a heavy subject burden. Alternative methods such as test weighing a breastfed infant before
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and after feeding can provide a good estimate using a sensitive balance [28,49–51]. Even test weighing
is reported in literature with different frequency throughout the day. This can vary from weighing the
infant at each feeding for 24 h [49] or 12 h [24] and in our study where we weighed the infants on three
occasions to calculate an average by recording the number of feeds per day. Even with this limitation
in our test weighing methodology our findings suggested that there were no differences in number
of feeds per day and per feed milk intake by infant between the groups of mothers with SCM or no
SCM. This observation is in agreement with Aryeetey et al., where infants were weighed for 12 h per
day [24]. In contrast, Manganaro et al. have reported an inverse relationship between HM sodium and
infant milk intake, however, that study was limited to only first week postpartum [52]. Overall this
may suggest that SCM may have an impact on infant milk intake but the effect is limited to the first
week only and has no to minimal impact at later stages of lactation as demonstrated in our study.
4.5. Infant Growth Parameters
A recent study on Guatemalan mothers exhibited low birth weight (lower WAZ score) and
head circumference in infants born to mothers who later developed SCM (Na:K > 0.6) as compared
to normal [53]. This observation is in agreement with our study wherein infants of mothers who
developed SCM were found to be lighter with a smaller head circumference which may be explained
due to greater incidence of shorter gestational age and higher rates of C-section. A similar observation
is also reported by Say et al. but on mastitic mothers [31].
After one month of lactation the incidence of SCM decreased drastically, the differences in infant
weight and head circumference also disappeared and were not significant over the study period.
Other studies have reported that subclinical mastitis causes poor infant weight gain [1,3,25,54]. These
studies were performed in African populations, and in some of them the incidence of HIV is high. In a
recent study among Mam-Mayan mothers at both early (2–46 d) and established (4–6 mo) lactation,
SCM was inversely associated with the weight-for-length Z-scores [55]. Since our study was performed
in well-nourished healthy European women, we speculate that this could have contributed to better
growth recovery on the infants of SCM mothers.
5. Conclusions
The strengths of our study include standardized and longitudinal HM collection, use of an
accepted diagnostic marker of SCM such as the ratios of Na and K in HM, detailed characterization of
several constituents of HM including energy, macronutrients, fatty acids, minerals, and an assessment
of infant growth over four months of lactation. As limitations, HM intake data was available only
in a subset of infants from France, breastfeeding and infant feeding behaviors were not captured, no
clinical data were available on mastitis or SCM, the study was not powered to perform country-wise
comparisons due to very small numbers in some countries and no formal sample size calculations
were done since the study was exploratory in nature.
In conclusion, for the first time, in the largest European standardized and longitudinal milk
collection study among lactating mothers, we demonstrate a high prevalence of SCM in early
lactation using a diagnostic marker of the ratio of Na and K in HM. The prevalence of SCM varies
remarkably across countries, suggestive of differences in breastfeeding practices and/or the frequencies
of C-section in these countries. SCM is significantly associated with alterations in the macro- and
micronutrient composition of HM; we hypothesize these alterations may be due to the opening of
the tight junctions and increased permeability of the mammary epithelium, acting potentially as a
mechanism to combat inflammation. Future studies should focus on understanding the relation of this
diagnostic marker of SCM with breastfeeding behaviors, HM output of the mother, infant growth and
developmental outcomes.
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